Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
1 - 10 of 62
- Understanding and targeting melanoma mesenchymal-like cells to improve response to immunotherapyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Spatio-temporal dissection of inter-cellular melanoma communication networks that contribute to resistance to immunotherapy.From1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Empowering precision medicine in melanoma: Exploring the potential of an implantable microdevice for large-scale drug screening in vivoFrom12 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Microfluidic tools to study single-cell responses and cell-cell communication in cancer applicationsFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of universal biomarkers of metastatic melanoma in CTCsFrom30 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Detection and prevention of early metastatic dissemination of melanomaFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Dissecting the cellular and molecular interaction networks that promote melanoma stemness at the perivascular niche.From1 Oct 2022 → TodayFunding: FWO senior postdoctoral fellowship
- Circulating tumor cells as a target of anti-metastatic treatment in melanoma.From1 Sep 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Molecular Cartography (Resolve Biosciences) , a single-molecule fluorescent in situ hybridization (smFISH) platform.From25 Aug 2022 → TodayFunding: Other federal scientific institutions
Publications
31 - 40 of 154
- The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival(2022)
Authors: Eleonora Leucci, Chris Marine
Pages: 15 - 25 - Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer(2022)
Authors: Ward Celus, Silvia Rivis, Ewout Landeloos, Yannick Van Herck, Abhishek Garg, Chris Marine, Mario di Matteo, Oliver Bechter, Max Mazzone
Pages: 126 - 141 - Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value(2021)
Authors: Jasper Wouters, Stein Aerts, Chris Marine
- Enhanced chromatin accessibility contributes to X chromosome dosage compensation in mammals(2021)
Authors: Lotte Vanheer, Ryan Nicolaas Allsop, Chris Marine, Thierry Voet, Vincent Pasque
- Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia(2021)
Authors: Chris Marine
Pages: 1204 - + - Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma(2021)
Authors: Vicky Katopodi, Sonia Cinque, Zorica Knezevic, Sara Adnane, Yvessa Verheyden, Panagiotis Karras, Francesca Bosisio, Oliver Bechter, Chris Marine, Eleonora Leucci
- Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma(2021)
Authors: Michael Dewaele, Panagiotis Karras, Nina Van Raemdonck, Dennis Pedri, Jonas Demeulemeester, Sara Vander Borght, Francesca Bosisio, Joost van den Oord, Isabelle Vanden Bempt, Diether Lambrechts, et al.
Pages: 1135 - + - Downregulation of the m6A RNA demethylase FTO in epithelial cancers promotes EMT-mediated tumor progression and confers sensitivity to Wnt inhibitors(2021)
Authors: Christine Desmedt, Eleonora Leucci, Chris Marine
Pages: 611 - 628 - Melanoma Models for the Next Generation of Therapies(2021)
Authors: Eleonora Leucci, Chris Marine
Pages: 610 - 631 - CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance(2021)
Authors: Chris Marine
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)